In trading on Wednesday, shares of Pfizer were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing hands as low as $27.93 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the S&P 500 ETF (SPY back on 12/31/1999 — you would have paid $146.88 per share. Fast forw ...

The latest trading session saw Pfizer (PFE) ending at $28.32, denoting a -1.32% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.37%. Elsewhere, the Dow lost 0.62%, while the tech-heavy Nasdaq lost 0.19%.Prior to today's trading, shares of the drugmaker had gained 6.06% over the past month. This has outpaced the Medical sector's gain of 4.61% and the S&P 500's gain of 1.56% in that time.The upcoming earnings release of Pfizer will be of great interest t ...

DAVOS, Switzerland—Albert Bourla has ambitious plans to turn around the situation at Pfizer. The market will decide if talk is cheap, but at least for now the stock looks cheap, or so the biopharma CEO wants investors to believe. And he put his money where his mouth is. ...

One of the most important companies during the peak of the COVID-19 pandemic was pharmaceutical giant Pfizer (PFE 1.06%). The company's breakthrough vaccine helped pave the way for a post-pandemic world. Over the last couple of years, demand for Pfizer's COVID-19 treatments helped spur record-breaking revenue.However, as pandemic concerns wane, some investors may wonder where Pfizer's next growth engine lies. While the company has several catalysts identified, I have my doubts on their prospects. And I'm no ...

Last year wasn't a particularly good one for Pfizer (PFE 1.06%). Even CEO Albert Bourla says so. "We missed our internal projections and also, we missed the expectations of The Street... And clearly, that was shown in our stock price performance, that was very, very bad," Bourla said at the JPMorgan Healthcare Conference last week.In October, the big pharma company slashed its forecasts for annual coronavirus vaccine and treatment sales due to lower-than-expected demand and announced a cost realignment plan ...

JHVEPhoto Pfizer Inc. (NYSE:PFE) stock has continued to reel from the exhaustion of COVID dollars. Specifically, the 2023 downturn has been primarily dragged by a faster-than-expected normalization of Comirnaty vaccine and Paxlovid COVID treatment uptakes. In addition to the $5.6 billion write-off on Paxlovid/Comirnaty inventory in Q3, management has also provided a weaker-than-expected guidance for said products in 2024. Specifically, management guides $8 billion in Comirnaty/Paxlovid revenue for 2024, und ...

Post-pandemic, the global bio-pharmaceutical sector, often overlooked, presents undervalued opportunities, notably in blue-chip stocks like Pfizer (NYSE:PFE). Following a 42% correction in the past year, PFE stock, with a 5.84% dividend yield, appears promising for 2024. The company anticipates $60 billion in revenue, signaling 9% year-on-year growth, supported by a compelling product pipeline.Here are some more reasons why investing in PFE stock will bring you to ultimate highs in 2024.The Excellent Bull C ...

In the latest trading session, Pfizer (PFE) closed at $29.40, marking a -0.61% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.15%. Elsewhere, the Dow lost 0.42%, while the tech-heavy Nasdaq added 0.09%.Heading into today, shares of the drugmaker had gained 3.28% over the past month, lagging the Medical sector's gain of 6.58% and the S&P 500's gain of 3.5% in that time.The investment community will be closely monitoring the performance of Pfizer in its forthcomin ...

Pharmaceutical giant Pfizer (PFE 0.37%) went through a growth spurt during the COVID-19 pandemic as one of the leading vaccine companies. But the windfall of billions of extra dollars in revenue and profits has gone as quickly as it came.Today, Pfizer stands roughly where it did before COVID-19 and shares trade at their lowest levels since the initial pandemic market crash in 2020. Is the stock a long-term buy after recently completing a blockbuster $43 billion acquisition?Here is what investors need to kno ...

Pfizer (PFE 0.37%) had a disastrous 2023, with its share price collapsing by 44%. It was one of the S&P 500's worst-performing stocks last year. The company's COVID-19 revenue nosedived as the demand for vaccinations waned, and the drugmaker can no longer count on that being a strong growth driver for the business.But with such a beaten-down valuation and Pfizer back to trading at 2020 levels, has the stock become too cheap of an investment to pass up? Is it only a matter of time before its shares rally aga ...